Anti-CD20 Agent Yields High Responses in Follicular Lymphoma

Rajat Bannerji, MD, PhD, discusses the safety and efficacy results of REGN1979 in the follicular lymphoma cohort enrolled in the phase I study of patients with relapsed/refractory B-Cell non-Hodgkin lymphoma who were previously treated with an anti-CD20 agent.

Rajat Bannerji, MD, PhD, associate professor of Medicine at the Robert Wood Johnson Medical School of Rutgers University and chief of the Hematologic Malignancies Clinic at the Rutgers Cancer Institute of New Jersey, discusses the safety and efficacy results of REGN1979 in the follicular lymphoma (FL) cohort enrolled in the phase I study of patients with relapsed/refractory B-Cell non-Hodgkin lymphoma who were previously treated with an anti-CD20 agent.

In patients with relapsed/refractory FL, a number of dose cohorts who received at least 80 mg of REGN1979 had a 100% objective response rate (ORR) with a 100% complete remission rate (CR), says Bannerji.

In patients who received above a 5 mL dose of REGN1979, there was a 95.6% ORR with a 77.3% CR. The study also evaluated the median progression-free survival (PFS) at about 6 months of follow-up. The median PFS observed in the FL group was 11.4 months. Bannerji considers this to be a reasonable PFS for heavily pretreated patients with FL.

For more information from Bannerji on the REGN1979 study:https://www.targetedonc.com/news/investigational-bispecific-antibody-signals-safety-and-efficacy-in-bcell-nhl.